v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Jan. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Other intangible assets        
Payment for contingent consideration liability $ 400      
Finite-lived intangible assets, period increase (decrease)       $ 511
Amortization of intangible assets   $ 3,500 $ 9,000 9,200
Future estimated amortization, 2026   1,900    
Future estimated amortization, 2027   1,800    
Future estimated amortization, 2028   1,800    
Future estimated amortization, 2029   1,700    
Future estimated amortization, 2030   $ 1,300    
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]   Other intangible assets    
Intangible asset impairment   $ 949 2,900 $ 136
Lower Revised Cash Flow Projections        
Other intangible assets        
Impairment charge     $ 1,800  
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]     Cost of products sold  
Lower Revised Cash Flow Projections | Augtyro        
Other intangible assets        
Impairment charge   $ 564 $ 1,400  
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]   Cost of products sold    
Lower Revised Cash Flow Projections | Inrebic        
Other intangible assets        
Impairment charge     280  
Lower Revised Cash Flow Projections | Abecma        
Other intangible assets        
Impairment charge     122  
Oncology Asset Due To Pipeline Reprioritization | In Process Research and Development        
Other intangible assets        
IPRD impairment charge   $ 385    
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]   Research and development    
Investigational Compound for Immunologic Diseases | Celgene | In Process Research and Development        
Other intangible assets        
IPRD impairment charge     $ 390  
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]     Research and development  
Investigational Compound for Hematologic Diseases | Celgene | In Process Research and Development        
Other intangible assets        
IPRD impairment charge     $ 590  
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]     Research and development